Some commentary from Milford funds monthly report for the month of Dec. keen to check on their upcoming Jan report soon to see if they continued their buying in Jan
Our best performer over the month was biotech Neuren Pharmaceuticals, which stormed 109.4% after announcing positive phase 3 trial results for its drug Trofinetide. Trofinetide looks likely to be the first FDA approved treatment for Rett Syndrome. We continued to build our position in Neuren after the results given the commercialisation opportunity is significantly de- risked.
Share Price, page-909
-
- There are more pages in this discussion • 10,021 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B | |||
| Open | High | Low | Value | Volume |
| $20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $20.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.68 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |